MDGL Valuation

Madrigal Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

313.400

-17.54(-5.300%)1D

Overview
Forecast
Valuation
Earnings

MDGL Relative Valuation

MDGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MDGL is overvalued; if below, it's undervalued.

Historical Valuation

Madrigal Pharmaceuticals Inc (MDGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.67 is considered Undervalued compared with the five-year average of -10.04. The fair price of Madrigal Pharmaceuticals Inc (MDGL) is between 623.57 to 849.86 according to relative valuation methord. Compared to the current price of 313.40 USD , Madrigal Pharmaceuticals Inc is Undervalued By 49.74%.

Relative Value

Fair Zone

623.57-849.86

Current Price：313.40

49.74%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

10.33

P/B

Median3y

38.84

Median5y

25.92

-5.34

FCF Yield

Median3y

-8.46

Median5y

-9.44

Competitors Valuation Multiple

The average P/S ratio for MDGL's competitors is 48.19, providing a benchmark for relative valuation. Madrigal Pharmaceuticals Inc Corp (MDGL) exhibits a P/S ratio of 9.67, which is -79.93% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MDGL.O

Madrigal Pharmaceuticals Inc

9.67

Average P/S: 48.19

6.96B